© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
May 11, 2021
Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
April 29, 2021
The future of clinical trials in a post pandemic world will rely on a patient-centered approach. Pharmacists can play a role to caring for these patients.
April 28, 2021
A session held at the HOPA Annual Meeting 2021 discussed investigational cancer drugs in clinical trials.
April 23, 2021
A session held at the HOPA Annual Meeting 2021 discussed best practices for optimizing opioid treatment in patients with cancer pain.
April 22, 2021
This indication is approved under accelerated approval based on tumor response rate and durability of response.
April 16, 2021
Research presented at the HOPA Annual Conference 2021 supported the benefit and feasibility of a pharmacy-led adherence and monitoring program for oral antineoplastic agents.
April 15, 2021
Findings presented at the Hematology/Oncology Pharmacists Association Annual Meeting 2021 discussed burnout and job dissatisfaction among oncology and hematology pharmacists.
At the HOPA Annual Conference 2021, Lakesha Butler, PharmD, BCCPS, discussed how pharmacists can disrupt the status quo to fight racism and work toward health equity for all.
April 14, 2021
Oncology programs provide the tools needed to improve patient outcomes.
April 01, 2021
Clinical trial data showed that the isatuximab (Sarclisa; Sanofi) regimen reduced risk of disease progression or death in patients with relapsed or refractory multiple myeloma.